A recent study has demonstrated that ipragliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT2), accelerates normotopic fat accumulation and inhibits liver steatosis [51]. This evidence concerns the gene SLC5A2 and fatty liver disease.